

CITATION REPORT

List of articles citing

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

DOI: 10.1016/j.ejim.2020.05.021

European Journal of Internal Medicine, 2020, 76, 43-49.

Source: <https://exaly.com/paper-pdf/84403564/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
321	Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome. 2020 , 2020, 8832986		1
320	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 1-112		2
319	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. 2020 , 80, 1929-1946		45
318	Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. 2020 , 7, 586221		30
317	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. 2020 , 24, 589		29
316	No time for pending confirmation of invasive fungal disease in critically ill COVID-19 patients-think empirical treatment. 2020 , 24, 588		5
315	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. 2020 , 383, 2333-2344		739
314	Current treatment options and safety considerations when treating adult-onset Still's disease. 2020 , 19, 1549-1558		8
313	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. 2020 , 88, 106869		32
312	Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. 2020 , 89, 107102		19
311	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2020 , 140, 86-104		14
310	New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19. 2020 , 889, 173615		6
309	Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. 2020 , 89, 107018		34
308	Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. 2020 , 25, 100459		50
307	GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?. 2020 , 2, e448-e449		5
306	IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. 2020 , 7, 583897		79
305	The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. 2020 , 72, 1529-1537		6

304	Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. 2020 , 100, 421-424	24
303	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114	11
302	Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: S More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumoniaSby Ferraccioli. 2020 ,	8
301	Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state. 2020 , 25, 1090-1094	7
300	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
299	Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive. 2020 , 9,	6
298	Targeting IL-6 in COVID-19. Response to: R Rational use of tocilizumab in COVID-19Sby Jain and Sharma. 2020 ,	1
297	More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia. 2020 ,	2
296	To immunosuppress: whom, when and how? That is the question with COVID-19. 2020 , 79, 1129-1131	11
295	COVID-19 and diabetes mellitus: how one pandemic worsens the other. 2020 , 21, 451-463	41
294	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. 2020 , 180, 114184	32
293	[Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia]. 2020 , 155, 548-556	27
292	Response to: R Rational use of tocilizumab in COVID-19Sby Jain and Sharma. 2020 ,	
291	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. 2020 , 2, e603-e612	173
290	Immunosuppressive Drugs and COVID-19: A Review. 2020 , 11, 1333	48
289	Tocilizumab. 2020 , 1813, 219-219	
288	The conundrum of interleukin-6 blockade in COVID-19. 2020 , 2, e579-e580	20
287	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. 2020 , 57, 236-243	23

286	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. 2020 , 7, 562142	11
285	High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. 2020 , 128, 64-68	21
284	Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: Colchicine treatment in community healthcare setting to prevent severe COVID-19 Sby Della-Torre. 2020 ,	4
283	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. <i>European Journal of Internal Medicine</i> , 2020 , 82, 23-24	3-9
282	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
281	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11	8
280	A "Window of Therapeutic Opportunity" for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019. 2020 , 11, 572635	6
279	Lack of tocilizumab effect on mortality in COVID19 patients. 2020 , 10, 17100	9
278	Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: Correspondence on: Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study Sby Della-Torre Sby Cheng and Zhang. 2020	5
277	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. 2020 , 18, 359	15
276	Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. 2020 , 4, 1178	185
275	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. 2020 , 131, 110698	46
274	Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. 2020 , 59, 1251-1260	16
273	Colchicine treatment in community healthcare setting to prevent severe COVID-19. 2020 ,	5
272	Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. 2020 , 9, 716-737	22
271	Is there any potential management against COVID-19? A systematic review and meta-analysis. 2020 , 28, 765-777	9
270	Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis. 2020 , 50, e13383	12
269	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. 2020 , 11, 584956	30

268	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. 2020 , 25,		15
267	Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?. 2020 , 11, 586765		11
266	Effects of Tocilizumab in COVID-19 patients: a cohort study. 2020 , 20, 964		17
265	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. 2020 , 18, 489		4
264	Mavrilimumab for severe COVID-19 - AuthorsSreply. 2020 , 2, e662-e663		3
263	Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of gene polymorphisms in novel coronavirus pneumonia. <i>Medicina Clínica (English Edition)</i> , 2020 , 155, 548-556	0.3	8
262	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. 2020 , 11, 588654		41
261	Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab. 2020 , 3, 29		4
260	Tocilizumab and liver injury in patients with COVID-19. 2020 , 13, 1756284820959183		13
259	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. 2020 , 9,		29
258	Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. <i>European Journal of Internal Medicine</i> , 2020 , 76, 21-22	3.9	14
257	Treating COVID-19 with colchicine in community healthcare setting. 2020 , 217, 108490		53
256	NK cells: A double edge sword against SARS-CoV-2. 2020 , 77, 100737		44
255	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. 2020 , 2, e465-e473		130
254	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. 2020 , 114, 102511		53
253	Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. 2020 , 30, 101139		4
252	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. 2020 , 79, 1277-1285		164
251	Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. 2021 , 80, 1-2		36

250	IL-18 and infections: Is there a role for targeted therapies?. 2021 , 236, 1638-1657	25
249	Late onset infectious complications and safety of tocilizumab in the management of COVID-19. 2021 , 93, 1459-1464	38
248	Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. 2021 , 19, 93-100	21
247	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53	13
246	Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. 2021 , 27, 52-66	69
245	Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies. 2021 , 72, e742-e749	54
244	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. 2021 , 133, 104071	21
243	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. 2021 , 181, 41-51	213
242	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. 2021 , 41, 303-314	27
241	Immunopathogenesis and treatment of cytokine storm in COVID-19. 2021 , 11, 316-329	118
240	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. 2021 , 11, 731-753	28
239	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. 2021 , 93, 2270-2280	20
238	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 83, 34-38	3.9 14
237	Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study. 2021 , 61, 406-411	3
236	What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies. 2021 , 56, 217-221	1
235	COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic Management of 2019 Novel Coronavirus Disease. 2021 , 44, 128-137	10
234	Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. 2021 , 77, 311-319	19
233	Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity?. <i>Cell Biochemistry and Function</i> , 2021 , 39, 35-47	4.2 16

232	Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?. 2021 , 16, 1-3	21
231	Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. 2021 , 93, 1620-1630	52
230	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287	11
229	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). 2021 , 27, 244-252	61
228	A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients. 2021 , 12, 20406223211039699	3
227	Efficacy and safety of tocilizumab in the management of COVID-19: A systematic review and meta-analysis of observational studies.	
226	Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant. 2021 , 30, 47-53	0
225	Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis. 2021 , 3, e0327	7
224	Immune and cellular damage biomarkers to predict COVID-19 mortality in hospitalized patients. 2021 , 2, 155-162	2
223	Efficacy and Safety of IL-6 Inhibitors in Patients with COVID-19 Pneumonia: A Systematic Review and Meta-Analysis of Multicentre, Randomised Trials.	
222	Incidence of Secondary Bacterial Infections Following Utilization of Tocilizumab for the Treatment of COVID-19 - A Matched Retrospective Cohort Study. 2021 , 13, 67-71	0
221	Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19. 2021 ,	7
220	Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results. 2021 , 391398821989334	2
219	Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. 2021 , 76, 970-979	80
218	Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. 2021 , 7, e06158	20
217	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.	
216	Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis. 2021 , 10, 73	9
215	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. 2021 , 22, 275-296	56

214	The Rheumatology Drugs for COVID-19 Management: Which and When?. 2021 , 10,	8
213	Potential Immunological Treatments in COVID-19 Patients.	0
212	Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab. 2021 , 60, 639-643	3
211	Interleukin-6 Trajectory and Secondary Infections in Mechanically Ventilated Patients With Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Treated With Interleukin-6 Receptor Blocker. 2021 , 3, e0343	2
210	EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection. 2021 , 26,	17
209	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. 2021 , 12, 607408	10
208	The right place for IL-1 inhibition in COVID-19. 2021 , 9, 223-224	21
207	Prophylaxis and treatment of COVID-19 related venous thromboembolism. 2021 , 133, 27-35	10
206	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. 2021 , 104, 433-440	18
205	Interleukin 1 α comprehensive review on the role of IL-1 α in the pathogenesis and treatment of autoimmune and inflammatory diseases. 2021 , 20, 102763	44
204	Tocilizumab for severe COVID-19 pneumonia: Experience from 5 geriatric Chinese patients with 6 months follow-up. 2021 , 2, 35-42	1
203	Proximal deep vein thrombosis and pulmonary embolism in COVID-19 patients: a systematic review and meta-analysis. 2021 , 19, 15	11
202	Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion. 2021 , 9, e0733	2
201	Worldwide Survey of COVID-19-Associated Arrhythmias. 2021 , 14, e009458	54
200	Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. 2021 , 22,	16
199	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. <i>European Journal of Internal Medicine</i> , 2021 , 86, 34-40	3-9 39
198	Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state. 2021 , 11, e042549	2
197	What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. 2021 , 16, e0249349	5

196	Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies.	0
195	The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. 2021 , 14, 1389-1392	
194	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. 2021 , 3, e253-e261	75
193	Circulating Calprotectin as a Biomarker of COVID-19 Severity. 2021 , 17, 431-443	21
192	Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. 2021 , 17, 499-511	12
191	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. 2021 , 12, 675678	18
190	CERC-002, a human anti-LIGHT mAb reduces respiratory failure and death in hospitalized COVID-19 ARDS patients.	0
189	Effect of anakinra on mortality in COVID-19: a patient level meta-analysis.	
188	Utility of hospitalization for elderly individuals affected by COVID-19. 2021 , 16, e0250730	4
187	Tocilizumab: From Rheumatic Diseases to COVID-19. 2021 , 27, 1597-1607	0
186	The role of IL-6 and IL-6 blockade in COVID-19. 2021 , 17, 601-618	10
185	Signaling through FcRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19. 2021 ,	12
184	A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic. 2021 , 11, 9784	6
183	Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. 2021 ,	0
182	No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study. 2021 , 100, e26023	2
181	Impact of tocilizumab on clinical outcomes in severe covid-19 patients and risk of secondary infection: A case-control study.	
180	Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). 2021 , 35, 1661-1670	7
179	Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. 2021 , 10, 71	13

178	COVID-19 and cancer: Sailing through the tides. 2021 , 221, 153417		2
177	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. 2021 , 10,		11
176	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. 2021 , 11, 95-109		1
175	High Levels of the Cleaved Form of Galectin-9 and Osteopontin in the Plasma Are Associated with Inflammatory Markers That Reflect the Severity of COVID-19 Pneumonia. 2021 , 22,		11
174	Therapeutic Agents Against COVID-19 with Clinical Evidence. 2021 , 27, 1608-1617		1
173	Brief review of the mRNA vaccines COVID-19. 2021 , 29, 645-649		11
172	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. 2021 ,		48
171	Low Serum Albumin Predicts Severe Outcomes in COVID-19 Infection: A Single-Center Retrospective Case-Control Study. 2021 , 13, 258-267		4
170	Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. 2021 , 16, e0251170		95
169	Use of monoclonal antibodies to IL-6 in patients with severe COVID-19. 2021 , 31, 263-271		
168	Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. 2021 , 87, 891-902		4
167	The Immunopathobiology of SARS-CoV-2 Infection. 2021 , 45,		1
166	Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. 2021 , 51, 890-897		11
165	Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis. 2021 ,		1
164	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 88, 52-62	3.9	4
163	Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. 2021 , 20, 1125-1136		7
162	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. 2021 , 9,		9
161	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2021 , 10, 1837-1885		10

160	Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. 2021 , 3, e0492		1
159	Liver injury in COVID-19: Known and unknown. 2021 , 9, 4980-4989		1
158	A single-center experience in use of tocilizumab in COVID-19 pneumonia in India. 2021 , 77, S296-S304		1
157	Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. 2021 , 10, 1677-1698		0
156	Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	7
155	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India. 2021 , 100, e26705		3
154	Pathogenesis and treatment of cytokine storm in COVID-19. 2021 , 45, 372-389		3
153	Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. 2021 , 14, 1001-1009		7
152	Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2. 2021 , 12, 706901		3
151	Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab. 2021 ,		2
150	The role of influenza A virus-induced hypercytokinemia. 2021 , 1-17		3
149	Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic. 2021 , 18,		8
148	Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. 2021 , e2295		9
147	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. 2021 , 16, e0257376		2
146	Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis. 2021 , 38, 5302-5316		0
145	Tocilizumab in COVID-19: The Cerrahpaş-PREDICT score. 2021 , 27, 1329-1335		6
144	How did COVID-19 affect medical and cardiology journals? A pandemic in literature. 2021 , 22, 840-847		2
143	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. 2021 , 41, 884-906		7

142	Effects of COVID-19 on the Musculoskeletal System: Clinician's Guide. 2021 , 13, 141-150	5
141	Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19. 2021 , 10,	4
140	Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study. 2021 , 111, 31-36	2
139	Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?. 2021 , 23, 861-873	3
138	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. 2021 , 3, e690-e697	38
137	Docking of disordered independent molecules of novel crystal structure of (N-(4-methoxyphenyl)-2-(3-methyl-2-oxo-3,4-dihydroquinoxalin-1(2H)-yl)acetamide as anti-COVID-19 and anti-Alzheimer's disease. Crystal structure, HSA/DFT/XRD. 2022 , 1247, 131420	9
136	[Cu(dipicolinoylamide)(NO ₃)(H ₂ O)] as anti-COVID-19 and antibacterial drug candidate: Design, synthesis, crystal structure, DFT and molecular docking. 2022 , 1247, 131348	9
135	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. 2021 , 18,	5
134	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. 2021 , 372, n84	186
133	The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman. 2021 , 11, 216-223	0
132	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
131	On the role of bacterial metalloproteases in COVID-19 associated cytokine storm. 2021 , 19, 7	1
130	Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients. 2021 , 4, 100086	8
129	Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis. 2021 , 71, 265-274	30
128	Coronavirus and other airborne agents with pandemic potential. 2020 , 17, 41-48	2
127	The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study. 2021 , 223, 581-588	3
126	Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. 2021 , 8, ofaa598	13
125	IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study.	84

124	Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center.	9
123	IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. 2020,	16
122	A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration.	2
121	Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis.	6
120	The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review.	7
119	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis.	3
118	Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia.	2
117	Prevalence and outcomes of co-infection and super-infection with SARS-CoV-2 and other pathogens: A Systematic Review and Meta-analysis.	3
116	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. 2020, 22, 290	17
115	Interleukin-6 signalling in health and disease. 2020, 9,	25
114	Autoimmunity as the comet tail of COVID-19 pandemic. 2020, 8, 3621-3644	35
113	Role of monoclonal antibody drugs in the treatment of COVID-19. 2020, 8, 4280-4285	21
112	Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. 2020, 30, 629-644	4
111	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020, 13, 4673-4695	20
110	Coronavirus disease 2019 in critically ill patients: can we re-program the immune system? A primer for Intensivists. 2020, 86, 1214-1233	1
109	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. 2020, 11, 598308	14
108	Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. 2020, 11, 615972	21
107	Tocilizumab and corticosteroids for COVID-19 treatment in elderly patients. 2020, 68, 197-203	6

106	Anticoagulants and immunosuppressants in COVID-19: Bullets to Defeat MicroCLOTS. 2020 , 23, 258-259	4
105	Clinical Management of Coronavirus Disease 2019, Covid-19. 2020 , 79, 317-324	1
104	Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. 2020 , 24, 771-776	6
103	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. 2020 , 8, e10322	25
102	Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence. 2020 , 12, e10869	17
101	V.I.T.A.M. in COVID 19: A Systematic Approach to a Global Pandemic. 2021 , 15, 11795484211047432	
100	Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. 2021 , 26, 1027-1040	7
99	Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. 2021 , 11, 152	4
98	Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review). 2021 , 24,	4
97	Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study. 2021 , 11, 19728	6
96	Immunosuppressant Management in Renal Transplant Patients with COVID-19. 2021 , 2021, 9318725	0
95	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9 2
94	Dental Healthcare Amid the COVID-19 Pandemic. 2021 , 18,	2
93	Drugs and liver injury: a not to be overlooked binomial in COVID-19. 2021 , 1-14	1
92	Hypercoagulability of COVID-19 and Neurological Complications: A Review. 2021 , 31, 106163	2
91	The COVID-19: Current understanding. 2020 , 13, 1998-2005	
90	Therapeutic Approach to Coronavirus Disease. 2020 , 67-97	0
89	Efficacy of Tocilizumab in Covid 19: A metanalysis of case series studies.	

88	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature.	0
87	Broad SARS-CoV-2 cell tropism and immunopathology in lung tissues from fatal COVID-19.	1
86	Invasive Fungal Infections Complicating COVID-19: A Narrative Review. 2021 , 7,	8
85	Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia. 2021 , e14997	2
84	Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study. 2021 , 21, 1127	2
83	Reply to Tleyjeh. 2021 , 72, e1155-e1156	
82	Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. 2022 , 1869, 119143	1
81	Use of psychopharmaceuticals during COVID-19 treatment. 2020 , 52, 89-97	1
80	Presentation and treatment of severe COVID pneumonia: current knowledge and experiences of Intensive Care Unit of the Clinic of Pulmonology, Clinical Center of Serbia. 2020 , 25, 7-22	
79	Impact of Timing of Tocilizumab Use in Hospitalized SARS-CoV-2 Infected Patients.	
78	Outcomes of treatment of severe COVID-19 pneumonia with tocilizumab: a report of two cases from Tunisia.. 2021 , 40, 126	
77	Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review. 2021 , 2021, 8903435	3
76	Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities. 2021 , 101522	5
75	Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy individuals: protocol for a systematic review and meta-analysis. 2021 , 11, e056106	0
74	Rationale and prognosis of repurposed drugs with risk stratification of COVID-19 patients requiring Oxygen supplementation: A systematic review and meta-analysis.	
73	Differences and similarities in diagnostic methods and treatments for Coronavirus disease 2019 (COVID-19): a scoping review.	
72	Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19.	
71	Therapeutic strategies against COVID-19. 2020 , 91, e2020038	2

70	Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study. 2021 , 46, 1-14	4
69	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. 2021 , 145, 112419	3
68	Tocilizumab in critically ill COVID-19 patients: An observational study. 2021 , 102, 108384	1
67	Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. 2021 ,	9
66	A possible potential COVID-19 drug candidate: Diethyl 2-(2-(2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetyl)hydrazono)malonate: Docking of disordered independent molecules of a novel crystal structure, HSA/DFT/XRD and cytotoxicity.. 2022 , 15, 103595	6
65	Research on SARS-COV-2 pandemic: a narrative review focused on the Italian contribution. 2021 , 1,	
64	Novel infectious causes of acute pancreatitis: A comprehensive review. 2021 , 7, 83	
63	An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).. 2022 , 105, 108536	4
62	Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis.. 2022 , 1	2
61	COVID-19 in Children and Adolescents: Characteristics and Specificities in Immunocompetent and Oncohematological Patients.. 2022 , 14, e2022009	1
60	Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.. 2022 ,	1
59	Is tocilizumab effective in cytokine release syndrome in patients diagnosed with COVID-19?: a retrospective preliminary study. 2022 , 8, 84-90	
58	Can l-carnitine reduce post-COVID-19 fatigue?. 2022 , 73, 103145	4
57	Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?. 2022 , 10,	2
56	Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review.. 2021 , 12, 804250	2
55	Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.. 2022 , 17534259211064602	1
54	Tocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients.. 2022 ,	1
53	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. 2021 ,	3

52	Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients.. 2022 , 8, e1292	2
51	Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review.. 2021 , 29, 495-503	5
50	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN TRANSLATION). 2021 , 7, 28-70	
49	Prevalence and Clinical Impact of Coinfection in Patients with Coronavirus Disease 2019 in Korea.. 2022 , 14,	2
48	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.. 2022 , 13, 795315	3
47	Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study.. 2022 , 11,	1
46	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry.. 2022 , 1	0
45	Molecular Docking for assessing Anti-fungal Competency of Hydroxychavicol, a Phenolic Compound of Betel Leaf (L.) against COVID-19 Associated Maiming Mycotic Infections.. 2022 , 1-43	1
44	Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis.. 2022 , 9, 838904	0
43	Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.. 2022 , 15, 2415-2425	1
42	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro.. 2022 , 17, 40	0
41	Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.. 2021 , 22, 317	1
40	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.. 2022 , 31, 9636897221090259	1
39	Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors. 2022 , 10, 34-47	
38	Image_1.JPEG. 2020 ,	
37	Image_2.JPEG. 2020 ,	
36	Table_1.docx. 2020 ,	
35	DataSheet_1.pdf. 2020 ,	

34	datasheet1.docx. 2020 ,		
33	Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.. 2022 , 68, 318-322		
32	Signaling Through FcR1IA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19.. 2022 , 13, 834988		1
31	Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.. <i>Medicina Clínica (English Edition)</i> , 2022 , 158, 301-307	0.3	
30	Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	
29	COVID-19 infection: an overview on cytokine storm and related interventions. 2022 , 19,		11
28	Practical points that gastrointestinal fellows should know in management of COVID-19. 2022 , 10, 5133-5145		
27	Drug combination therapies for SARS-CoV-2 (COVID-19) treatment. 2022 , 181-203		
26	Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia. 2022 , 2022, 1-7		1
25	Biologics in COVID-19 So Far: Systematic Review. 2022 , 15, 783		0
24	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. 13,		
23	Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment. <i>CNS Drugs</i> ,	6.7	3
22	Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis. <i>Medicina Clínica (English Edition)</i> , 2022 , 158, 608-612	0.3	
21	NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients. <i>Cell Biochemistry and Function</i> ,	4.2	0
20	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022 , 11, 269-297	3	0
19	Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants. <i>Journal of Personalized Medicine</i> , 2022 , 12, 1103	3.6	0
18	Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19). 2022 , 58, 1076		0
17	Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. 2022 , 3,		2

- 16 Immune-related adverse events of biological immunotherapies used in COVID-19. 13, ○
- 15 Comparative Analysis Of Immunosuppressive Therapy Effectiveness In COVID-19 Patients. **2022**, 11, ○
- 14 Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019. **2022**, 26, 1091-1098 ○
- 13 Case Report: Effectiveness of tocilizumab in obese patient for treatment of severe COVID-19 pneumonia. 11, 1152 ○
- 12 Evaluation of Drug-Induced Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection. **2022**, 10, 2045 1
- 11 Neutrophil infiltration and myocarditis in patients with severe COVID-19: A post-mortem study. 9, ○
- 10 Uso de Tocilizumab en pacientes hospitalizados por neumonía por COVID 19. Estudio de cohorte. **2022**, ○
- 9 Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. **2022**, 23, 14462 ○
- 8 Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review. 28, 6662-6688 ○
- 7 Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Pre-vaccination Stage during the Pandemic in Mexico. **2022**, 2022, 1-6 ○
- 6 Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study. **2023**, 59, 53 ○
- 5 Comparison of clinical outcomes of intensive care patients with COVID-19 pneumonia receiving and not receiving tocilizumab treatment. **2023**, 5, 39-46 ○
- 4 Innate immune responses in COVID-19. **2023**, 63-128 ○
- 3 Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics. **2023**, 12, 2301 ○
- 2 Severe COVID-19 Pneumonia in a Three-Year-Old with Congenital Iron and B12 Deficiency Anemia of Unknown Etiology: A Case Report. **2023**, 10, 616 ○
- 1 The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). **2023**, 43, 147-163 ○